Array BioPharma Inc. (ARRY) Rating Lowered to Strong Sell at BidaskClub

Paterniano Del Favero
Августа 13, 2017

American Gp owns 10,223 shares or 0% of their U.S. portfolio. Raymond James & Associates owns 10,400 shares for 0% of their portfolio.

Franklin Resources Inc decreased Axis Capital Holdings Ltd (NYSE:AXS) stake by 148,227 shares to 849,176 valued at $55.43M in 2016Q4. Intl Gp reported 83,069 shares. Analysts reported that the Price Target for Array BioPharma Inc. might touch $15 high while the Average Price Target and Low price Target is $12.33 and $9 respectively. 158.02 million shares or 7.81% more from 146.57 million shares in 2016Q3 were reported. The Illinois-based Balyasny Asset Mngmt Limited Liability Corp has invested 0.07% in Array Biopharma Inc (NASDAQ:ARRY). Cooke & Bieler Lp holds 1.23M shares. Spark Inv Mngmt Llc has 0.02% invested in Charter Financial Corp (NASDAQ:CHFN) for 16,000 shares. 10,000 were accumulated by North Star Management Corporation. State Bank Of Montreal Can reported 1,508 shares. Pnc Fin Service owns 204,870 shares. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.04, Bloomberg Earnings reports. Therefore 75% are positive. The 10-year historical median operating margin of Array BioPharma Inc is -89.25%. (ARRY)'s latest closing price distance was at -5.17% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 2.66% and 4.09% compared with the 20 Day Moving Average. BidaskClub raised Array BioPharma from a "strong sell" rating to a "sell" rating in a report on Thursday, June 22nd. The rating was maintained by Jefferies with "Buy" on Monday, June 12. (ARRY) most recent 13F filing, the company has 42 new institutional holders - accounting for 8.07 million shares of its common stock. Piper Jaffray Companies set a $14.00 target price on Array BioPharma and gave the stock a buy rating in a report on Wednesday, May 31st. Zacks Investment Research upgraded Array BioPharma from a "sell" rating to a "hold" rating in a research note on Friday. The stock of Array Biopharma Inc (NASDAQ:ARRY) earned "Buy" rating by Cantor Fitzgerald on Tuesday, July 18. It dived, as 34 investors sold ARRY shares while 36 reduced holdings.

Array BioPharma (NASDAQ:ARRY) last released its earnings results on Wednesday, August 9th. The correct version of this piece of content can be viewed at Cantor Fitzgerald set a $13.00 target price on shares of Array BioPharma and gave the stock a "buy" rating in a report on Wednesday.

Since March 28, 2017, it had 0 buys, and 2 sales for $633,150 activity. LEFKOFF KYLE sold 45,000 shares worth $401,400. According to these analysts, the Low Revenue Estimate for Array BioPharma 6 Million and the High Revenue Estimate is 49.5 Million.

Array BioPharma a biopharmaceutical firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Analyst mean recommendation on a stock by the analyst community is at 1.80. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). A stock price loss will yield a negatively weighted alpha. The Company's binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its down 0.58, from 1.88 in 2016Q3.

Other hedge funds also recently added to or reduced their stakes in the company. Its down 0.58, from 1.88 in 2016Q3. Driehaus Mgmt Lc invested in 0.05% or 93,238 shares. Monetary Mgmt Gp owns 600 shares. Old Natl Bank & Trust In holds 0.01% or 11,449 shares in its portfolio. Moreover, Wells Fargo Mn has 0% invested in Carbonite Inc (NASDAQ:CARB) for 51,311 shares. The profitability rank of the company is 2 (out of 10). The average volume stands around 3.05 million shares. Blackrock Fund has invested 0% in Graham Corporation (NYSE:GHM). Juno Therapeutics Inc (NASDAQ:JUNO) was raised too. (NASDAQ:MYL), 11 have Buy rating, 0 Sell and 6 Hold. Therefore 65% are positive. Mobileye had 43 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Constellation Brands, Inc. JP Morgan maintained Constellation Brands, Inc. 435,183 were accumulated by Goldman Sachs Group. The stock, after opening at $8.74, touched a high of $8.81 before paring much of its gains. The company was maintained on Friday, July 14 by RBC Capital Markets. (NYSE:STZ) on Thursday, October 8 with "Outperform" rating. The rating was maintained by Jefferies on Monday, June 12 with "Buy". The firm earned "Buy" rating on Friday, June 30 by Goldman Sachs.

Altre relazioni

Discuti questo articolo